- Home
- CINT vs CVAC Comparison
CINT vs CVAC Comparison
Compare CINT & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- CVAC
- Stock Information
- Founded
- CINT 1995
- CVAC 2000
- Country
- CINT Brazil
- CVAC Germany
- Employees
- CINT N/A
- CVAC N/A
- Industry
- CINT EDP Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- CVAC Health Care
- Exchange
- CINT Nasdaq
- CVAC Nasdaq
- Market Cap
- CINT 803.4M
- CVAC 764.4M
- IPO Year
- CINT 2021
- CVAC 2020
- Fundamental
- Price
- CINT $5.96
- CVAC $5.45
- Analyst Decision
- CINT Buy
- CVAC Hold
- Analyst Count
- CINT 7
- CVAC 3
- Target Price
- CINT $7.61
- CVAC $6.83
- AVG Volume (30 Days)
- CINT 101.9K
- CVAC 2.2M
- Earning Date
- CINT 08-15-2025
- CVAC 08-14-2025
- Dividend Yield
- CINT N/A
- CVAC N/A
- EPS Growth
- CINT 53.80
- CVAC N/A
- EPS
- CINT 0.24
- CVAC 0.87
- Revenue
- CINT $444,135,000.00
- CVAC $566,039,775.00
- Revenue This Year
- CINT $526.02
- CVAC N/A
- Revenue Next Year
- CINT $12.77
- CVAC $24.04
- P/E Ratio
- CINT $24.89
- CVAC $6.26
- Revenue Growth
- CINT 3.04
- CVAC 787.60
- 52 Week Low
- CINT $4.42
- CVAC $2.37
- 52 Week High
- CINT $8.04
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- CINT 52.04
- CVAC 65.07
- Support Level
- CINT $5.89
- CVAC $5.36
- Resistance Level
- CINT $5.94
- CVAC $5.45
- Average True Range (ATR)
- CINT 0.18
- CVAC 0.08
- MACD
- CINT 0.02
- CVAC -0.05
- Stochastic Oscillator
- CINT 72.73
- CVAC 58.00
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.